Lantern AI Predicts Blood-Brain Barrier Permeability

Lantern Pharma has unveiled a novel AI-driven method for predicting blood-brain barrier (BBB) permeability, with its patent application receiving a favorable PCT search report. This strengthens its path to approval and highlights its innovation.

The technology can process up to 100,000 molecules per hour with top-tier accuracy, holding five of the top eleven spots on the Therapeutic Data Commons Leaderboard. By identifying BBB-permeable compounds early, it could accelerate drug development for brain cancers and CNS disorders, reducing time and costs in early-stage research.

Learn more